Steven Cohen’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,525,549
Closed -$56.1M – 4579
2026
Q2
$56.1M Buy
+1,525,549
New +$41.3M 0.06% 391
2025
Q3
– Sell
-168,779
Closed -$2.31M – 2702
2025
Q2
$2.31M Sell
168,779
-67,227
-28% -$645K ﹤0.01% 1241
2025
Q1
$2.61M Sell
236,006
-81,108
-26% -$865K 0.01% 1159
2024
Q4
$3.38M Sell
317,114
-1,189,532
-79% -$14.2M 0.01% 1069
2024
Q3
$19.1M Sell
1,506,646
-942,631
-38% -$14M 0.05% 432
2024
Q2
$41.1M Buy
2,449,277
+1,337,257
+120% +$19M 0.11% 248
2024
Q1
$16.7M Buy
1,112,020
+986,020
+783% +$16.1M 0.04% 521
2023
Q4
$1.89M Sell
126,000
-81,733
-39% -$1.06M ﹤0.01% 1229
2023
Q3
$2.91M Buy
+207,733
New +$3.33M 0.01% 1040
2020
Q1
– Sell
-222,024
Closed -$7.41M – 1095
2019
Q4
$7.41M Buy
222,024
+164,222
+284% +$4.48M 0.04% 436
2019
Q3
$1.38M Buy
57,802
+290
+0.5% +$9.48K 0.01% 644
2019
Q2
$2.07M Sell
57,512
-206,087
-78% -$7.6M 0.01% 647
2019
Q1
$9.7M Buy
263,599
+198,599
+306% +$8.33M 0.04% 412
2018
Q4
$2.8M Buy
65,000
+12,954
+25% +$582K 0.01% 668
2018
Q3
$2.46M Buy
+52,046
New +$2.42M 0.01% 733

Other funds holding URGN

Steven Cohen's URGN Position: Q3 2026 in Review

Steven Cohen sold out of UroGen Pharma (URGN) in Q3 2026, closing a stake of 1,525,549 shares — an estimated $56.1M sold.

Steven Cohen first reported a position in URGN in Q3 2018 and held it in 15 quarters. The position peaked at $56.1M in Q2 2026. 221 funds tracked by Wall St. Rank hold URGN as of Q3 2026.

  • Steven Cohen reported no remaining UroGen Pharma position as of Q3 2026 after selling out during the quarter.
  • Steven Cohen sold 1,525,549 UroGen Pharma shares in Q3 2026, an estimated $56.1M.
  • Steven Cohen first reported a position in UroGen Pharma in Q3 2018 and held it in 15 quarters.
  • Steven Cohen's UroGen Pharma position peaked at $56.1M in Q2 2026.
  • 221 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.